ストックスクリーナーアプリを入手
0.5464
1.19%
0.0064
前日終値:
$0.54
開ける：
$0.544
24時間の取引高:
255.55K
Relative Volume:
0.39
時価総額：
$15.00M
収益：
$5.61M
当期純損益:
$-55.45M
株価収益率:
-0.2126
EPS:
-2.5703
ネットキャッシュフロー:
$-42.35M
1週間 パフォーマンス:
-4.58%
1か月 パフォーマンス:
+3.68%
6か月 パフォーマンス:
-46.43%
1年 パフォーマンス:
-40.13%
1日の値動き範囲:
$0.54
$0.5699
1週間の範囲:
$0.5303
$0.5999
52週間の値動き範囲:
$0.476
$2.48
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
名前
Citius Pharmaceuticals Inc
セクター
電話
(908) 967-6676
住所
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.5464 | 15.00M | 5.61M | -55.45M | -42.35M | -2.5703 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-30 | アップグレード | D. Boral Capital | Hold → Buy |
| 2021-11-30 | 開始されました | Maxim Group | Buy |
Citius Pharmaceuticals Inc (CTXR) 最新ニュース
Citius Pharmaceuticals Inc (CTXR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Citius Pharmaceuticals Inc (CTXR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Citius Pharmaceuticals Inc (CTXR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Citius Pharmaceuticals Inc (CTXR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Citius Oncology Inc (CTOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Citius Pharmaceuticals Inc (CTXR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Citius Oncology Inc (CTOR) Institutional Confidence - TradingKey
Citius Pharmaceuticals Inc (CTXR) Institutional Confidence - TradingKey
Citius Pharmaceuticals Inc (CTXR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Citius Pharmaceuticals Inc (CTXR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
[EFFECT] CITIUS ONCOLOGY, INC. SEC Filing - Stock Titan
Citius Oncology (CTOR) stake updated by majority holder Citius Pharma - Stock Titan
[EFFECT] Citius Pharmaceuticals, Inc. SEC Filing - Stock Titan
Citius Highlights LYMPHIR Combo Data in Gynecologic Cancers - TipRanks
Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data - Stock Titan
Citius Oncology (NASDAQ: CTXR) shares early Phase 1 LYMPHIR cancer data - Stock Titan
Citius Oncology (NASDAQ: CTOR) highlights Phase 1 LYMPHIR plus pembrolizumab results - Stock Titan
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies - BioSpace
Citius Oncology presents study data on LYMPHIR combination By Investing.com - Investing.com Australia
Citius Oncology presents study data on LYMPHIR combination - Investing.com
LYMPHIR combo study finds 24% response, disease control up to 35 months - Stock Titan
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies – Company AnnouncementFT.com - Financial Times
Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - simplywall.st
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting - marketscreener.com
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts? - Yahoo Finance
TENK News & Events - Intellectia AI
Citius Pharmaceuticals (NASDAQ: CTXR) registers 5.43M resale shares from warrants - Stock Titan
Citius Oncology (CTOR) registers 6.82M warrant shares; May 2026 financing steps - Stock Titan
5 Best Rated Penny Stocks to Buy According to Wall Street Analysts - Insider Monkey
CTXR Stock Price, Quote & Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Citius Oncology (NASDAQ: CTOR) majority approves warrant and conversion issuances - Stock Titan
H.C. Wainwright Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Citius Pharmaceuticals Reports Increased Losses in Q2 FY 2026 - Intellectia AI
Citius Pharmaceuticals Price Target Announced at $4.00/Share by HC Wainwright & Co. - Moomoo
H.C. Wainwright Initiates Citius Pharmaceuticals(CTXR.US) With Buy Rating, Announces Target Price $4 - Moomoo
CTXR Assumes Buy Rating by HC Wainwright & Co. -- Price Target a - GuruFocus
Citius Pharmaceuticals (CTXR) price target increased by 20.00% to 6.12 - MSN
Citius Pharmaceuticals Q2 Net Income USD -21. - Moomoo
Is Citius Pharmaceuticals (CTXR) Undervalued After Q2 FY2026 Upd - GuruFocus
CTXR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Citius Pharmaceuticals reports $5.6M H1 revenue from LYMPHIR; Q2 net loss $21.2M - TradingView
CTXR: $5.6M in LYMPHIR revenue, 80% gross margin, $21.2M Q2 net loss, $41.5M new financing - TradingView
[8-K] CITIUS ONCOLOGY, INC. Reports Material Event - Stock Titan
Citius Pharmaceuticals Q2 revenue rises on LYMPHIR launch - TradingView
Citius Pharmaceuticals (CTXR) logs $5.6M LYMPHIR sales, deeper losses in Q2 2026 - Stock Titan
Citius Pharmaceuticals, Inc. 3Q FY2026: Revenue $1.67M, EPS $(0.95) — 10-Q Summary - TradingView
CTXR: LYMPHIR launch spurred revenue growth, but losses rose sharply due to a major contract termination - TradingView
Citius Oncology 2Q Loss/Shr 27c >CTOR - Moomoo
Citius Pharmaceuticals (CTXR) starts LYMPHIR sales but faces heavy loss and going concern risk - Stock Titan
Citius Oncology (NASDAQ: CTOR) flags going concern, adds $25.0 million loan - Stock Titan
Citius Pharmaceuticals Inc (CTXR) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):